CAS: 898280-07-4; N4-(5-Cyclopropyl-1H-Pyrazol-3-yl)-N2-((3-Isopropylisoxazol-5-yl)Methyl)-6-(4-Methylpiperazin-1-yl)Pyrimidine-2,4-Diamine

该化合物是一个小分子,主要作为动脉抑制剂发挥作用; 已经调查了该分子的潜在治疗应用,特别是各种癌症的治疗; 化合物有选择地针对细胞发育和存活的细胞信号路径中涉及的特定动脉,使其成为癌症治疗的候选体; XL 228 展示了一种独特的化学结构,有助于其生物活动,尽管详细的结构信息通常是专有的; 在临床前研究中,它显示出抑制肿瘤生长和克服对其他疗法的抗药性的前景; 与许多调查药物一样, XL228 的安全和功效通过临床试验进行评估,其药理动力特性,如吸收,分布,代谢和排泄,对于了解其作为治疗剂的潜力至关重要; 进一步的研究对于充分阐明其行动机制以及建立临床使用的最佳施药疗法十分必要.

结构式图片

合成工艺路线路线简述

  • 109-01-3 + 1449314-09-3 = 898280-07-4
    反应条件:1.1 Solvents: Dimethylacetamide; 15 Min,88 °C; 255 Min,90 °C
    标题:Process Development And Multikilogram Syntheses Of Xl228 Utilizing A Regioselective Isoxazole Formation And A Selective Snar Reaction To A Pyrimidine Core
    作者:Guz,Nathan R.; Leuser,Helena; Goldman,Erick
    参考文献:Organic Process Research & Development 日期:2013 卷标:17(8) 页码:1066-1073
N-(4,6-Dichloropyrimidin-2-yl)-N-(Prop-2-Ynyl)Acetamide置于potassium Hydrogencarbonate体系中,用 N,N-二甲基乙酰胺,醋酸异丙酯 作为反应溶剂,化学反应 39.5H,反应生成 N4-(5-环丙基-1H-吡唑-3-基)-N2-[[3-异丙基-5-异恶唑基]甲基]-6-(4-甲基-1-哌嗪基)-2,4-嘧啶二胺
参考文献:Process Development And Multikilogram Syntheses Of Xl228 Utilizing A Regioselective Isoxazole Formation And A Selective Snar Reaction To A Pyrimidine Core
标题:Process Development And Multikilogram Syntheses Of Xl228 Utilizing A Regioselective Isoxazole Formation And A Selective Snar Reaction To A Pyrimidine Core
摘要:Route Scouting,Process Development,And Multikilogram Syntheses Of An Igf-1R/src/bcr-Abl Inihibitor Are Reported. Key Aspects Of The Developed Route Are A Regioselective [3 + 2] Isoxazole Formation On A Pyrimidine Core And A Selective Snar Addition Of An Aryl Amine To A Symmetrical Dichloro Substituted Pyrimidine. The Route Contains Six Synthetic Steps And Was Demonstrated Twice On Scale,Delivering 4.6 And 11.2 Kg (25% And 16% Overall Yield),For Phase I Clinical Studies.
DOI:10.1021/op400137M

海关参考信息

专利信息


专利号:WO-2025128098-A1
优先权日:2023-12-13
标 题 :Solid oral dosage forms, kits, and methods of using the same
发明人:LI YING; LANGER ROBERT; TRAVERSO CARLO
权利人:MASSACHUSETTS INST TECHNOLOGY; BRIGHAM & WOMENS HOSPITAL INC
摘要:Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).

专利号:US-12180228-B2
优先权日:2019-06-05
标题:Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
发明人:MOVASSAGHI MOHAMMAD; OLSSON CHASE ROBERT; SCOTT TONY Z; CHEAH JAIME; PAYETTE JOSHUA NATHANIEL
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.
上海兴默生物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.xmobio.com
电话: 0086 13524779951; 13524779951👤
📞上海兴默生物技术有限公司 ⚠️参考联系方式

销售电话:0086 13524779951; 13524779951
邮箱:sales@xmobio.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Edilova MI, Law JC, Zangiabadi S, Ting K, Mbanwi AN, Arruda A, Uehling D, Isaac M, Prakesch M, Al-Awar R, Minden MD, Abdul-Sater AA, Watts TH. The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia. Oncoimmunology. 2021 Sep 23;10(1):1943234. doi: 10.1080/2162402X.2021.1943234.
2: Patel A, Li L, Anand A. Systematic review: functional outcomes and complications of intramedullary nailing versus plate fixation for both-bone diaphyseal forearm fractures in children. Injury. 2014 Aug;45(8):1135-43. doi: 10.1016/j.injury.2014.04.020. Epub 2014 May 2. 95(2):155. doi: 10.1308/rcsann.2013.95.2.155a.
4: Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev. 2012 Jun;38(4):292-302. doi: 10.1016/j.ctrv.2011.07.008. Epub 2011 Sep 9. 7(1):14-30. doi: 10.2174/157489212798357930.

合成参考文献


参考文献:10.1124/mol.119.115964
摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知